A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants

NCT ID: NCT07301723

Last Updated: 2025-12-24

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-31
• Study Completion Date: 2026-04-30

Brief Summary

The goal of this clinical trial is to learn about the absolute bioavailability of cenerimod in healthy participants. It will also provide information about the safety of cenerimod.

Participants will receive one tablet with cenerimod, followed by an intravenous (i.v.) infusion with a 14C-radiolabeled cenerimod microtracer (cenerimod with a very low dose of radioactivity) 6 hours later.

Participants will stay at the clinic for a total of 4 days, and will return to the clinic for further tests over the course of approximately 3 months.

Conditions

Healthy Subjects

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Cenerimod

Cenerimod is administered as a single oral dose followed by a single i.v. radiolabeled dose 6 h later.

Group Type: EXPERIMENTAL

Cenerimod (oral)

Intervention Type: DRUG

A single dose of cenerimod, administered as an oral tablet at a strength of 4 mg

14C-Cenerimod (i.v.)

Intervention Type: DRUG

A single i.v. dose of 7.5 µg 14C-radiolabeled cenerimod (34.5 kBq), with administration starting 6 h after administration of the oral dose.

Interventions

Cenerimod (oral)

A single dose of cenerimod, administered as an oral tablet at a strength of 4 mg

Intervention Type: DRUG

14C-Cenerimod (i.v.)

A single i.v. dose of 7.5 µg 14C-radiolabeled cenerimod (34.5 kBq), with administration starting 6 h after administration of the oral dose.

Intervention Type: DRUG

Other Intervention Names

ACT-334441; 14C-ACT-334441

Eligibility Criteria

Inclusion Criteria

1. Signed and dated informed consent form in a language understandable to the participant prior to any trial-mandated procedure.

2. Healthy male participant aged between 18 and 65 years (inclusive) at Screening. Healthy is defined as no clinically relevant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs measurements, and clinical laboratory evaluations.

3. Body mass index 18.0-29.9 kg/m^2 (inclusive) at Screening.

4. Ability to communicate well with the investigator, in a language understandable to the participant, and to understand and comply with the trial requirements.

5. Systolic blood pressure 90-140 mmHg, diastolic blood pressure 60-90 mmHg, and pulse rate 55-100 bpm (inclusive), measured on either arm (same arm used for both Screening and on the day of study treatment administration), after 5 min in the supine position at Screening and prior to oral dosing on the day of study treatment administration.

6. 12-lead safety ECG: QTcF < 450 ms, QRS interval < 120 ms, PR interval < 200 ms, and heart rate 55-100 bpm, and without clinically relevant abnormalities, measured after 5 min in the supine position at Screening and prior to oral dosing on the day of study treatment administration.

Exclusion Criteria

1. Previous exposure to cenerimod.

2. Known hypersensitivity to any excipients of the trial intervention formulations.

3. Known hypersensitivity or allergy to natural rubber latex.

4. History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the trial interventions (appendectomy and herniotomy allowed, cholecystectomy not allowed).

5. Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the evaluation of the trial results.

6. Clinically relevant history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.

7. Lymphopenia (< 0.9 x 10^9 cells/L) at Screening or on the day prior to study treatment administration.

8. Family history of sick-sinus syndrome.

9. Any cardiac condition or illness (including ECG abnormalities) with a potential to increase the cardiac risk of the participant based on the standard 12-lead ECG at Screening or pre-dose on the day of study treatment administration.

10. History or presence of cardiac rhythm disorders (e.g., sinoatrial heart block, sick-sinus syndrome, 2nd or 3rd degree atrioventricular block, long QT syndrome, symptomatic bradycardia, atrial flutter, or atrial fibrillation).

11. Previous treatment with antiarrhythmic medications of class Ia or III within 2 weeks or 5 elimination half-lives, whichever is longer, prior to oral dosing.

12. Clinically relevant findings in clinical laboratory tests (hematology, clinical chemistry, and urinalysis) at Screening or on the day prior to study treatment administration.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Viatris Innovation GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Viatris Innovation GmbH

Other Identifiers

ID-064-108

Identifier Type: -

Identifier Source: org_study_id